There are currently 21 active clinical trials seeking participants for Small Cell Lung Cancer research studies. The states with the highest number of trials for Small Cell Lung Cancer participants are Texas, California, Florida and New York.
Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.
NCT05271292
Recruiting
This is a Phase 1b/2, single-arm, open-label, dose-escalation study including 2 stages: Phase 1b: Dose-Escalation Stage (Single-Dose and Consecutive-Dose Periods) Phase 2: recommended Phase 2 dose (RP2D) of chiauranib will be given to all patients enrolled in this phase once daily for 28-day cycles continuously with no interruption between cycles.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/18/2024
Locations: California Cancer Associates-Encintas, Encinitas, California +10 locations
Conditions: Advanced Solid Malignant Tumor, Small Cell Lung Cancer
Register for Updates
Phase 2 Safety and Efficacy Evaluation of AL8326 in ≥2nd Line SCLC
NCT05363280
Recruiting
This trial is a Phase II trial designed to evaluate the safety and efficacy of using oral AL8326 , a multi-targeted receptor Tyrosine Kinase Inhibitor( TKI) , to recurrent, advanced, or metastatic small cell lung cancer (SCLC) patients who need ≥2nd line treatment .
Gender:
All
Ages:
18 years and above
Trial Updated:
03/08/2024
Locations: Cleveland Clinic Florida, Weston, Florida +3 locations
Conditions: Small Cell Lung Cancer
Register for Updates
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
NCT06047379
Recruiting
This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype, and the safety, pharmacokinetics and efficacy of a repeated dose regimen of NEO212 when given with select SOC for the treatment of solid tumor patients with radiographically confirmed uncontrolled brain metastasis.... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/13/2024
Locations: Precision NextGen Oncology, Beverly Hills, California +1 locations
Conditions: Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Microsatellite Instability-High Solid Malignant Tumor, Mismatch Repair Deficient Solid Malignant Tumor, Microsatellite Instability-High Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Squamous Cell Carcinoma, Urothelial Carcinoma
Register for Updates
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
NCT03881488
Recruiting
This is a Phase 1, open-label, first-in-human study of CTX-471 administered as a monotherapy or in combination with pembrolizumab in patients with metastatic or locally advanced malignancies that have progressed while receiving an approved PD-1 or PD-L1 inhibitor. The study will be conducted in 2 treatment arms (Monotherapy Arm 1 and Combination Arm 2). Each arm will have two parts: Part 1 Dose Escalation and Part 2 Dose Expansion.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/29/2024
Locations: Ocala Oncology Center, Ocala, Florida +9 locations
Conditions: Locally Advanced Solid Tumor, Metastatic Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Mesothelioma, Melanoma, Head and Neck Cancer
Register for Updates
89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
NCT05563272
Recruiting
A prospective, open-label, phase 2 study to explore CAIX expression through 89Zirconium-labelled girentuximab deferoxamine (89Zr-girentuximab) PET/CT imaging in patients with solid tumors.
Gender:
All
Ages:
Between 18 years and 95 years
Trial Updated:
01/24/2024
Locations: Biogenix Molecular, LLC, Miami, Florida +4 locations
Conditions: Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Glioblastoma Multiforme, Cholangiocarcinoma, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma, Nasopharyngeal Carcinoma, Non Small Cell Lung Cancer, Small Cell Lung Cancer, Epithelial Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Soft Tissue Sarcoma
Register for Updates
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
NCT04199741
Recruiting
The purpose of this study is to look at how safe 89Zr-DFO-SC16.56 is, and how it is processed by the body in people with small cell lung cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/10/2024
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Small Cell Lung Cancer, Small Cell Lung Carcinoma
Register for Updates
A Phase 1/2 Study of BA3071 as Monotherapy and in Combination With a PD-1 Blocking Antibody in Patients With Advanced Solid Tumors
NCT05180799
Recruiting
The objective of this study is to assess safety and efficacy of BA3071 in solid tumors
Gender:
All
Ages:
18 years and above
Trial Updated:
12/08/2023
Locations: The Angeles Clinic and Research Institute, Los Angeles, California +8 locations
Conditions: Solid Tumor, Adult, NSCLC, Urothelial Carcinoma, Gastric Cancer, Small Cell Lung Cancer, Hepatocellular Carcinoma, Cervical Carcinoma, Melanoma, Renal Cell Carcinoma, Carcinoma
Register for Updates
IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer
NCT04434482
Recruiting
This is an open-label, multi-center, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, PK characteristics and anti-tumor activity of PARP inhibitor IMP4297 and temozolomide combination therapy in patients with advanced solid tumors and with ES-SCLC who develops disease progression after 1L platinum-based regimen.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/28/2023
Locations: GenHarp Clinical Solutions, Evergreen Park, Illinois +20 locations
Conditions: Advanced Solid Tumours, Small Cell Lung Cancer
Register for Updates
Rapid Autopsy Protocol for Patients With Small Cell Lung Cancer
NCT05889546
Recruiting
This is pilot study to establish a rapid autopsy program in Small Cell Lung Cancer (SCLC) at the Indiana University Simon Comprehensive Cancer Center and outline the components necessary for tumor tissue collection.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/27/2023
Locations: Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana +1 locations
Conditions: Small Cell Lung Cancer
Register for Updates